Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
Status: | Completed |
---|---|
Conditions: | Chronic Obstructive Pulmonary Disease, Pulmonary |
Therapuetic Areas: | Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | Any |
Updated: | 11/18/2012 |
Start Date: | March 2012 |
End Date: | September 2013 |
Contact: | Boehringer Ingelheim Call Center |
Email: | clintriage.rdg@boehringer-ingelheim.com |
Phone: | 1-800-243-0127 |
Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (Low Dose, High Dose), Tiotropium (Low Dose, High Dose) and Olodaterol (One Dose Only) (Oral Inhalation, Delivered by the RESPIMAT Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The trial is intended to characterize the lung function profile of tiotropium + olodaterol
fixed dose combinations (low dose and high dose) in Chronic Obstructive Pulmonary Disease
(COPD) patients where patients will perform pulmonary function tests (spirometry) and
bodyplethysmography tests at regular intervals for 24 hours at the end of 6 week treatment
periods. Each patient will receive four out of six treatments (incomplete cross-over).
Inclusion criteria:
1. Diagnosis of chronic obstructive pulmonary disease
2. Relatively stable airway obstruction with a post-bronchodilator FEV1< 80% of
predicted normal and a post-bronchodilator FEV1/FVC <70%
3. Male or female patients, 40 years of age or older
4. Smoking history of more than 10 pack years
5. Ability to perform technically acceptable pulmonary function tests and maintain
records
6. Ability to inhale medication in a competent manner from the RESPIMAT Inhaler and from
a metered dose inhaler (MDI)
Exclusion criteria:
1. significant disease other than COPD
2. clinically relevant abnormal lab values
3. history of asthma
4. diagnosis of thyrotoxicosis
5. diagnosis of paroxysmal tachycardia
6. history of myocardial infarction
7. unstable or life-threatening cardiac arrhythmia
8. Hospitalization for heart failure within the past year
9. known active tuberculosis
10. malignancy for which patient has undergone resection, radiation therapy or
chemotherapy within last five years
11. history of life-threatening pulmonary obstruction
12. history of cystic fibrosis
13. clinically evident bronchiectasis
14. history of significant alcohol or drug abuse
15. history of thoracotomy with pulmonary resection
16. oral or patch ß-adrenergics
17. oral corticosteroid medication at unstable doses
18. regular use daytime oxygen therapy for more than one hour per day
19. Pulmonary rehabilitation program in the six weeks prior to the screening visit
20. Investigational drug within one month or six half lives (whichever is greater) prior
to screening visit
21. Known hypersensitivity to ß-adrenergic drugs, BAC, EDTA
22. Pregnant or nursing women
23. Women of childbearing potential not using a highly effective method of birth control
24. Patients who have previously been randomised in this study or are currently
participating in another study
25. Patients who are unable to comply with pulmonary medication restrictions prior to
randomisation
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials